Physician profile

Patrick Joseph Cindrich

Neurological Surgery · Rupert, ID

NPI 1821101395

$8,597.09

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$37.96

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Choice Spine, LLC $3,154.11 2022
Surgalign Spine Technologies, INC. $2,450.46 2022
Life Spine, INC. $1,145.04 2020
Medacta USA, INC. $1,078.51 2021
Centinel Spine, LLC $607.57 2021
Medtronic, INC. $64.17 2021-2022
Nalu Medical, INC. $32.70 2022-2024 Nalu Neurostimulation System
Alphatec Spine, INC $28.80 2019
Si-Bone, INC. $24.54 2024
Stimwave Technologies Incorporated $11.19 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Patrick Joseph Cindrich

$8,597.09

in general payments reported 2019-2025

Years
2019-2024
Top company
Choice Spine, LLC

https://glasscript.com/doctor/82160/patrick-joseph-cindrich

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.